PRESS RELEASES

Date Title and Summary View
Toggle Summary Regulus Regains Compliance with NASDAQ Listing Requirements
LA JOLLA, Calif. , Oct. 18, 2018 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it received notice from The Nasdaq Stock Market LLC "NASDAQ" indicating
View HTML
Toggle Summary Regulus Therapeutics Announces Reverse Stock Split
LA JOLLA, Calif. , Oct. 4, 2018 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that at the special meeting of stockholders, held September 28, 2018,
View HTML
Toggle Summary Regulus to Participate in Fireside Chat at the Chardan Genetic Medicines Conference
LA JOLLA, Calif. , Oct. 2, 2018 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that Jay Hagan , President and Chief Executive Officer of Regulus, will
View HTML
Toggle Summary Regulus to Present at the Cantor Fitzgerald Global Healthcare Conference
LA JOLLA, Calif. , Sept. 27, 2018 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that Jay Hagan , President and Chief Executive Officer of Regulus, will
View HTML
Toggle Summary Regulus Provides Pipeline Updates
Hepatitis B virus Lead Compound Demonstrates Compelling Data in Preclinical Studies Glioblastoma multiforme Lead Compound Demonstrates Significant Survival Benefit as Monotherapy and in Combination with Temozolomide in Preclinical Disease Models Improvement in Multiple Key Endpoints Observed in
View HTML
Toggle Summary Regulus Reports Second Quarter 2018 Financial Results and Recent Updates
Corporate Restructuring and Pipeline Focus Expected to Extend Cash Runway Amendment to Term Loan to Provide Additional Interest-Only Period LA JOLLA, Calif. , Aug. 9, 2018 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and
View HTML
Toggle Summary Regulus Announces Strategic Update and Corporate Restructuring
Efforts Aimed at Extending Cash Runway to mid-2019 LA JOLLA, Calif. , July 5, 2018 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced a strategic update and
View HTML
Toggle Summary Regulus Reports First Quarter 2018 Financial Results and Pipeline Progress
Two pre-clinical programs advance towards clinical candidates Conference call today at 5:00 p.m. ET LA JOLLA, Calif. , May 10, 2018 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting
View HTML
Toggle Summary Regulus to Provide First Quarter 2018 Financial Results on May 10, 2018
Conference Call and Webcast to Follow LA JOLLA, Calif. , May 3, 2018 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced it will provide first quarter 2018 financial
View HTML
Toggle Summary Regulus Initiates Multiple Ascending Dose Study in Healthy Volunteers of RGLS4326 for the Treatment of ADPKD
Initial safety and pharmacokinetic results from single ascending dose study support advancement LA JOLLA, Calif. , May 1, 2018 /PRNewswire/ --  Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs,
View HTML